Ushering in Liquid Biopsy for the Microsatellite Status: Advantages and Caveats.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31527165.
- Also identified by DOI 10.1158/1078-0432.CCR-19-2585.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Microsatellite instable tumors often respond to immune checkpoint blockade (ICB), however, tumor tissue is unavailable/insufficient in some patients. Two groups are reporting a blood-based assessment of the microsatellite status validated in tumor tissue and by clinical benefit in patient receiving ICB. Both approaches are highly appealing with a few caveats.<i>See related articles by Georgiadis et al., p. 7024, and Willis et al., p. 7035</i>.
Medical subject headings
- Microsatellite Instability
- Neoplasms